PhD candidate Asli Munzur looked at blood mutations caused by two cancer treatments to work out potential side effects of a ...

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Today's biotech news covers Pluvicto's prostate cancer play, J&J's big bets on bladder, lung, and talent, and more. Skip to Main Content Manage alerts for this article ...

PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with: ...

ATNM-400 is Actinium's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer, which is supported by preclinical data demonstrating higher efficacy than Pluvicto (PSMA-617-Lutetium-177 ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

“To anyone with prostate cancer, I’d say, get in there early and ask about Pluvicto™. It saved my life.” The Purdue-IU partnership exemplifies the seamless “bench to bedside” power of work by ...

FRANKFURT, June 2 (Reuters) - Novartis , opens new tab said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...